drugset / Trial / NCT02033317

An Open-Label, Multiple Dose Study to Evaluate the Pharmacology, Safety, and Tolerability of Patiromer in Participants on Hemodialysis

NCT02033317

Phase 2 Terminated 6 enrolled Relypsa, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This study assessed the pharmacodynamic effects of patiromer on serum potassium in participants on hemodialysis.

Timeline

Start
2008-08
Primary completion
2008-12
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Patiromer Other / unclassified 5 g Oral

Indications

No indication recorded.